Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Structure-based rational design enables efficient discovery of a new selective and potent AKT PROTAC degrader
Cheng‐Liang Zhu, Xiaomin Luo, Tian Tian, et al.
European Journal of Medicinal Chemistry (2022) Vol. 238, pp. 114459-114459
Closed Access | Times Cited: 19

Showing 19 citing articles:

Annual review of PROTAC degraders as anticancer agents in 2022
Xiao Wang, Zhao-Long Qin, Na Li, et al.
European Journal of Medicinal Chemistry (2024) Vol. 267, pp. 116166-116166
Closed Access | Times Cited: 56
Characteristic roadmap of linker governs the rational design of PROTACs
Yawen Dong, Tingting Ma, Ting Xu, et al.
Acta Pharmaceutica Sinica B (2024) Vol. 14, Iss. 10, pp. 4266-4295
Open Access | Times Cited: 24
Targeted protein degradation: advances in drug discovery and clinical practice
Guangcai Zhong, Xiaoyu Chang, Weilin Xie, et al.
Signal Transduction and Targeted Therapy (2024) Vol. 9, Iss. 1
Open Access | Times Cited: 19
Biophysical and Computational Approaches to Study Ternary Complexes: A ‘Cooperative Relationship’ to Rationalize Targeted Protein Degradation
Jake A. Ward, Carles Perez‐Lopez, Cristina Mayor‐Ruiz
ChemBioChem (2023) Vol. 24, Iss. 10
Open Access | Times Cited: 35
Addressing the Reciprocal Crosstalk between the AR and the PI3K/AKT/mTOR Signaling Pathways for Prostate Cancer Treatment
Fabio Raith, Daniel H. O’Donovan, Clara Lemos, et al.
International Journal of Molecular Sciences (2023) Vol. 24, Iss. 3, pp. 2289-2289
Open Access | Times Cited: 25
Integrated Direct-to-Biology Platform for the Nanoscale Synthesis and Biological Evaluation of PROTACs
Rebecca Stevens, Enrique Bendito-Moll, David Battersby, et al.
Journal of Medicinal Chemistry (2023) Vol. 66, Iss. 22, pp. 15437-15452
Closed Access | Times Cited: 18
Multiomic profiling of breast cancer cells uncovers stress MAPK-associated sensitivity to AKT degradation
Emily C. Erickson, Inchul You, Grace E. Perry, et al.
Science Signaling (2024) Vol. 17, Iss. 825
Open Access | Times Cited: 6
Rational Proteolysis Targeting Chimera Design Driven by Molecular Modeling and Machine Learning
Shuoyan Tan, Zhuo Chen, Ruiqiang Lu, et al.
Wiley Interdisciplinary Reviews Computational Molecular Science (2025) Vol. 15, Iss. 2
Closed Access
Strategies for overcoming resistance to Bruton's tyrosine kinase inhibitor zanubrutinib
Hana Dostálová, Vladimı́r Kryštof
Hematological Oncology (2024) Vol. 42, Iss. 4
Open Access | Times Cited: 3
Novel Allosteric Inhibitor-Derived AKT Proteolysis Targeting Chimeras (PROTACs) Enable Potent and Selective AKT Degradation in KRAS/BRAF Mutant Cells
Xufen Yu, Jia Xu, Kaitlyn M. Cahuzac, et al.
Journal of Medicinal Chemistry (2022) Vol. 65, Iss. 20, pp. 14237-14260
Open Access | Times Cited: 16
Extracellular Interactors of the IGF System: Impact on Cancer Hallmarks and Therapeutic Approaches
Caterina Mancarella, Andrea Morrione, Katia Scotlandi
International Journal of Molecular Sciences (2024) Vol. 25, Iss. 11, pp. 5915-5915
Open Access | Times Cited: 1
AKT kinases as therapeutic targets
Dalal Hassan, Craig W. Menges, Joseph R. Testa, et al.
Journal of Experimental & Clinical Cancer Research (2024) Vol. 43, Iss. 1
Open Access | Times Cited: 1
An Integrated Direct-to-Biology Platform for the Nanoscale Synthesis and Biological Evaluation of PROTACs
Rebecca Stevens, Enrique Bendito-Moll, David Battersby, et al.
(2023)
Open Access | Times Cited: 2
An updated patent review of AKT inhibitors (2020 – present)
Linjie Li, Guo Yu, Yang Lu, et al.
Expert Opinion on Therapeutic Patents (2023) Vol. 33, Iss. 9, pp. 549-564
Closed Access | Times Cited: 2
Down-regulation of AKT proteins slows the growth of mutant-KRAS pancreatic tumors
Chuankai Chen, Yaping Jiang, Inchul You, et al.
bioRxiv (Cold Spring Harbor Laboratory) (2024)
Open Access
Down-Regulation of AKT Proteins Slows the Growth of Mutant-KRAS Pancreatic Tumors
Chuankai Chen, Yaping Jiang, Inchul You, et al.
Cells (2024) Vol. 13, Iss. 12, pp. 1061-1061
Open Access
Computer-Aided Identification of Kinase-Targeted Small Molecules for Cancer: A Review on AKT Protein
Erika Primavera, Deborah Palazzotti, Maria Letizia Barreca, et al.
Pharmaceuticals (2023) Vol. 16, Iss. 7, pp. 993-993
Open Access | Times Cited: 1
An Integrated Direct-to-Biology Platform for the Nanoscale Synthesis and Biological Evaluation of PROTACs
Rebecca Stephens, Enrique Bendito-Moll, David Battersby, et al.
(2023)
Open Access | Times Cited: 1
Multi-omic profiling of breast cancer cells uncovers stress MAPK-associated sensitivity to AKT degradation
Emily C. Erickson, Inchul You, Grace E. Perry, et al.
bioRxiv (Cold Spring Harbor Laboratory) (2022)
Open Access
Page 1

Scroll to top